PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|September 6, 2016
Syngene International Establishes R&D Center for Amgen
Author(s)Pharmaceutical Technology Editors
The company established a dedicated research center in Bangalore, India for Amgen.
Advertisement
On September 6, 2016, Syngene International, a contract research organization based in Asia, announced that it has established a multi-disciplinary drug discovery and development center for Amgen in Bangalore, India. The center is named Syngene Amgen Research and Development Center (SARC) and is Syngene’s fourth exclusive R&D center. The company currently operates facilities for Bristol-Myers Squibb, Abbott Nutrition, and Baxter.
The center will be staffed by more than 100 Syngene scientists, working in close association with Amgen researchers. The center is customized to meet Amgen’s functional requirements and is configured to minimize solvent and effluent waste.
Syngene has partnered with Amgen in a variety of discovery and development projects. With the establishment of SARC, this association now extends into a multi-discipline collaboration, spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharmaceutical development.
Source: Syngene International
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement